Cargando…

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

OBJECTIVES: To examine whether baseline anti-cyclic citrullinated peptide-2 (CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate (MTX) in the 2-year AMPLE (Abatacept versus adaliMumab comParison in bioL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sokolove, Jeremy, Schiff, Michael, Fleischmann, Roy, Weinblatt, Michael E, Connolly, Sean E, Johnsen, Alyssa, Zhu, Jin, Maldonado, Michael A, Patel, Salil, Robinson, William H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819608/ https://www.ncbi.nlm.nih.gov/pubmed/26359449 http://dx.doi.org/10.1136/annrheumdis-2015-207942

Ejemplares similares

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
por: Schiff, Michael, et al.
Publicado: (2016)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
por: Degboé, Yannick, et al.
Publicado: (2020)

Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
por: Jabado, Omar, et al.
Publicado: (2021)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
por: Wells, Alvin F, et al.
Publicado: (2014)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients
por: Kida, Daihei, et al.
Publicado: (2020)

Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

Ample subvarieties of algebraic varieties
por: Hartshorne, Robin
Publicado: (1970)

Citrullination of fibrinogen: generation of neoepitopes and enhancement of immunostimulatory properties
por: Robinson, William H, et al.
Publicado: (2012)

COVID-19 in Children: An Ample Review
por: Ciuca, Ioana M
Publicado: (2020)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
por: Takahashi, Nobunori, et al.
Publicado: (2013)

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
por: Dervieux, Thierry, et al.
Publicado: (2019)

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
por: Atzeni, Fabiola, et al.
Publicado: (2006)

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
por: Alten, Rieke, et al.
Publicado: (2022)

Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials
por: Keystone, Edward C, et al.
Publicado: (2020)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment
por: Elkayam, Ori, et al.
Publicado: (2010)

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
por: Tymms, Kathleen, et al.
Publicado: (2021)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Colorectal endometriosis: ample data without definitive recommendations
por: Moawad, GN, et al.
Publicado: (2021)

Ample evidence suggests SARS-CoV-2 triggers polyradiculitis
por: Finsterer, J., et al.
Publicado: (2022)

Ample evidence suggests SARS-CoV-2 triggers polyradiculitis
por: Finsterer, J., et al.
Publicado: (2022)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
por: Malaviya, Anshuman P, et al.
Publicado: (2012)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
por: Abdel Fattah, Nermeen SA, et al.
Publicado: (2009)

Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis
por: Won, Pureun, et al.
Publicado: (2021)

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
por: Alten, Rieke, et al.
Publicado: (2023)

Reply to “Ample evidence suggests SARS-CoV-2 triggers polyradiculitis”
por: Esteban Molina, A., et al.
Publicado: (2022)

Reply to “Ample evidence suggests SARS-CoV-2 triggers polyradiculitis”
por: Esteban Molina, A., et al.
Publicado: (2022)

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
por: Weijers, Laure, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_482gsggoms973ai6betd36ao52